|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Adapt_Pharma
gptkb:Cangene_Corporation
gptkb:PaxVax
|
|
gptkbp:CEO
|
gptkb:Haywood_Miller
|
|
gptkbp:contractedBy
|
gptkb:U.S._government
|
|
gptkbp:focusesOn
|
infectious diseases
biodefense
opioid overdose
public health threats
|
|
gptkbp:formerName
|
gptkb:BioPort_Corporation
|
|
gptkbp:foundedBy
|
gptkb:Fuad_El-Hibri
|
|
gptkbp:foundedYear
|
1998
|
|
gptkbp:fundedBy
|
gptkb:U.S._Department_of_Health_and_Human_Services
|
|
gptkbp:hasFacility
|
gptkb:Baltimore,_Maryland
gptkb:Birmingham,_Alabama
gptkb:Gaithersburg,_Maryland
gptkb:Rockville,_Maryland
gptkb:San_Diego,_California
gptkb:Bern,_Switzerland
gptkb:Lansing,_Michigan
gptkb:Winnipeg,_Canada
|
|
gptkbp:headquartersLocation
|
gptkb:Gaithersburg,_Maryland,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Emergent BioSolutions
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Fuad_El-Hibri
gptkb:Haywood_Miller
gptkb:Richard_S._Lindahl
gptkb:Robert_Kramer
|
|
gptkbp:listedOn
|
gptkb:Fortune_1000
|
|
gptkbp:manufacturer
|
gptkb:COVID-19_vaccines_(for_Johnson_&_Johnson_and_AstraZeneca)
|
|
gptkbp:notableEvent
|
gptkb:COVID-19_vaccine_manufacturing_contamination_(2021)
|
|
gptkbp:notableProduct
|
gptkb:Anthrax_Vaccine_Adsorbed
gptkb:BioThrax
gptkb:Narcan
gptkb:Raxibacumab
gptkb:Vaxchora
|
|
gptkbp:numberOfEmployees
|
approximately 2,000
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:specializesIn
|
vaccines
antidotes
antitoxins
contract development and manufacturing
plasma-derived therapeutics
|
|
gptkbp:stockExchange
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:EBS
|
|
gptkbp:tradedOn
|
gptkb:NYSE:EBS
|
|
gptkbp:website
|
https://www.emergentbiosolutions.com/
|
|
gptkbp:bfsParent
|
gptkb:Anthrax_Vaccine_Adsorbed_(AVA)
gptkb:Peter_Thiel
|
|
gptkbp:bfsLayer
|
4
|